Search

Join us to explore the latest advancements in dementia research and the emergence of novel disease-modifying agents for early Alzheimer's Disease.

Australia is on the brink of approval and availability of at least two agents. Comprehensive care will stretch from genetic and risk factor screening, new diagnostic pathways, treatment delivery, adverse events monitoring, follow-up, and after care.

This is an important shift in dementia treatment and care, with profound implications for all health sectors, from primary to tertiary care and substantial shifts in health and aged care budgets.

This webinar is for anyone who works in aged care. Leading palliative care experts will talk about education and training opportunities that will help you to deliver high-quality, person-centred palliative care.

Learn what steps you can take to build your confidence, skills and knowledge to care for people who have a life-limiting illness.

Part of the Fertility Webinar Series AMH testing-when, why, what to do with it Reproductive Genetic Carrier Screening.

AMH: The clinical significance of AMH lies in its ability to help assess whether an individual’s AMH level falls outside the expected range for their age. This information is valuable in understanding how well a person’s fertility aligns with their chronological age, and the extent to which their AMH result deviates from the typical range. This Session will cover interpreting AMH results and discuss when to refer patients for further follow up.

Reproductive Carrier Screening: Australian obstetric guidelines recommend that ANY couple or person who is planning a pregnancy, or are in the first trimester of pregnancy, should be offered reproductive genetic carrier screening. Due to the recent introduction of medicare rebates for Genetic Carrier screening, there is an increase in patients accessing this test, and therefore the need to understand options for patients following results. This session will discuss Genetic Carrier Screening test options, interpreting results and next steps including options for preimplantation genetic testing (PGT-A & PGT-M) for high risk patients.

The PHN is proud to commission BaptistCare to deliver the End-of-Life Care Coordination Pilot for older people residing in the Newcastle Local Government Area.

You are invited to attend this upcoming webinar, gaining insight into research based exercise interventions for individuals living with cancer and chronic conditions. At the Kaden Centre each person will be assessed by a physiotherapist or exercise physiologist, will have a personal program developed and will be supervised through each session of that program by a physiotherapist, exercise physiologist or qualified trainer

The education session will be presented by Hunter New England Population Health Unit and will provide important information regarding the following:

• Gain knowledge about the lymphoedema services provided at the Kaden Centre.

• Evaluate the evidence supporting the integration of exercise as a management strategy for lymphoedema post breast cancer treatment.

• Information on risk factors for developing secondary lymphoedema and who/when to refer on

• Overview of treatment and management strategies for people at risk or who have developed secondary lymphoedema

SPEAKER: Julia Britton – Senior Physiotherapist & Lymphedema Specialist, Kaden Centre

Test

From Monday 1 July 2024, the National Bowel Cancer Screening Program will lower the eligible screening age from 50 to 45.

The PHN held its inaugural Palliative and End-of-Life Care Symposium at Belmont 16s Sailing Club on Friday 14^th June, with 75 per cent of delegates rating the symposium ‘five stars’.

Welcome to the PHN Disaster Management Alert System. Here, primary care providers can quickly report emergencies or disruptions affecting business continuity to receive timely assistance and support.